Cargando…
Dermatomyositis Flare With Immune Checkpoint Inhibitor Therapy for Melanoma
Immune checkpoint inhibitor (ICI) medications have seen expanded use in the management of numerous malignancies. These therapies encompass a unique spectrum of immune-related adverse events (irAEs). Rheumatological irAEs from ICIs have been described in various case reports; however, limited literat...
Autores principales: | Thomas, Rachel, Patel, Hamish, Scott, Joshua |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cureus
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8106943/ https://www.ncbi.nlm.nih.gov/pubmed/33981507 http://dx.doi.org/10.7759/cureus.14387 |
Ejemplares similares
-
Hyperprogression in Pediatric Melanoma Metastatic to the Breast Treated with a Checkpoint Inhibitor
por: Bernal Vaca, Laura, et al.
Publicado: (2019) -
Nivolumab-Induced Toxic Epidermal Necrolysis: Rare but Fatal Complication of Immune Checkpoint Inhibitor Therapy
por: Kim, Michael C, et al.
Publicado: (2021) -
Anti-melanoma Differentiation-Associated Gene 5 (Anti-MDA5) Dermatomyositis: A Case Presentation
por: Ruppel, Tyler, et al.
Publicado: (2022) -
Dermatomyositis with Extensive Calcification in an Adult
por: Presley, Bradley C, et al.
Publicado: (2012) -
Dermatomyositis Anteceding Lung Adenocarcinoma
por: Lim, Jin Lee, et al.
Publicado: (2020)